A landmark in drug discovery based on complex natural product synthesis

被引：29

作者：

Kawano, Satoshi ^{[1
]}

Ito, Ken ^{[1
]}

Yahata, Kenzo ^{[2
]}

Kira, Kazunobu ^{[1
]}

Abe, Takanori ^{[1
]}

Akagi, Tsuyoshi ^{[1
]}

Asano, Makoto ^{[1
]}

Iso, Kentaro ^{[1
]}

Sato, Yuki ^{[1
]}

Matsuura, Fumiyoshi ^{[3
]}

Ohashi, Isao ^{[1
]}

Matsumoto, Yasunobu ^{[1
]}

Isomura, Minetaka ^{[1
]}

Sasaki, Takeo ^{[1
]}

Fukuyama, Takashi ^{[1
]}

Miyashita, Yusuke ^{[4
]}

Kaburagi, Yosuke ^{[1
]}

Yokoi, Akira ^{[1
]}

Asano, Osamu ^{[1
]}

Owa, Takashi ^{[5
]}

Kishi, Yoshito ^{[2
]}

机构：

[1] Eisai & Co Ltd, Tsukuba, Ibaraki, Japan

[2] Harvard Univ, Cambridge, MA 02138 USA

[3] Eisai & Co Ltd, Bunkyo Ku, Tokyo, Japan

[4] Eisai & Co Ltd, Kamisu, Ibaraki, Japan

[5] Eisai Inc, Woodcliff Lake, NJ USA

来源：

SCIENTIFIC REPORTS | 2019年 / 9卷 / 1期

关键词：

ANTITUMOR POLYETHER MACROLIDES; ANTINEOPLASTIC AGENTS; HALICHONDRIN-B; BREAST-CANCER; TUBULIN; ANTIBODY; MICROTUBULES; CETUXIMAB; DISEASE; BINDING;

D O I：

10.1038/s41598-019-45001-9

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Despite their outstanding antitumour activity in mice, the limited supply from the natural sources has prevented drug discovery/development based on intact halichondrins. We achieved a total synthesis of C52-halichondrin-B amine (E7130) on a >10 g scale with >99.8% purity under GMP conditions. Interestingly, E7130 not only is a novel microtubule dynamics inhibitor but can also increase intratumoural CD31-positive endothelial cells and reduce alpha-SMA-positive cancer-associated fibroblasts at pharmacologically relevant compound concentrations. According to these unique effects, E7130 significantly augment the effect of antitumour treatments in mouse models and is currently in a clinical trial. Overall, our work demonstrates that a total synthesis can address the issue of limited material supply in drug discovery/development even for the cases of complex natural products.

引用

页数：9

共 50 条

[31] Pure compound libraries; a new perspective for natural product based drug discovery
Bindseil, KU
Jakupovic, J
Wolf, D
Lavayre, J
Leboul, J
van der Pyl, D
DRUG DISCOVERY TODAY, 2001, 6 (16) : 840 - 847
[32] A novel approach in drug discovery:: Synthesis of estrone-talaromycin natural product hybrids
Tietze, LF
Schneider, G
Wölfling, J
Fecher, A
Nöbel, T
Petersen, S
Schuberth, I
Wulff, C
CHEMISTRY-A EUROPEAN JOURNAL, 2000, 6 (20) : 3755 - 3760
[33] Natural Product Synthesis as a Source of Inspiration and Discovery
Shimokawa, Jun
JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN, 2018, 76 (05) : 458 - 461
[34] Industrial natural product chemistry for drug discovery and development
Bauer, Armin
Broenstrupt, Mark
NATURAL PRODUCT REPORTS, 2014, 31 (01) : 35 - 60
[35] Natural product derived privileged scaffolds in drug discovery
Davison, Emma K.
Brimble, Margaret A.
CURRENT OPINION IN CHEMICAL BIOLOGY, 2019, 52 : 1 - 8
[36] Sustainable development of natural product research in drug discovery
Wang, Y.
PLANTA MEDICA, 2008, 74 (09) : 897 - 897
[37] Natural product derived privileged scaffolds in drug discovery
Brimble, Margaret
Davison, Emma
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258
[38] Natural product hybrids as new leads for drug discovery
Tietze, LF
Bell, HP
Chandrasekhar, S
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2003, 42 (34) : 3996 - 4028
[39] Natural product drug discovery in the artificial intelligence era
Saldivar-Gonzalez, F. I.
Aldas-Bulos, V. D.
Medina-Franco, J. L.
Plisson, F.
CHEMICAL SCIENCE, 2022, 13 (06) : 1526 - 1546
[40] Evolving paradigms for natural-product drug discovery
Geoffrey A.Cordell
NationalScienceReview, 2022, 9 (11) : 10 - 11

← 1 2 3 4 5 →